Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of AMY-101 for COVID-19-related ARDS
2020-001550-22Phase 2Active
- Sponsor
- Amyndas Pharmaceuticals
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of AMY-101 in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Amyndas Pharmaceuticals. Primary endpoint: Time to clinical improvement. Started Aug 2020; status: active.
02
Drugs
AMY-101
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001550-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001550-22.